Is Acorda Therapeutics, Inc. overvalued or undervalued?

As of 3 October 2023, Acorda Therapeutics, Inc. has moved from fair to attractive. The company is currently undervalued. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Sales (P/S) ratio of 3.0, and a Price-to-Book (P/B) ratio of 1.8. In comparison, peer companies such as Amgen, with a P/E of 15.2, and Biogen, with a P/S of 4.5, indicate that Acorda is trading at a discount relative to its industry peers.
Additionally, Acorda's recent stock performance has outpaced the Sensex, reinforcing the notion that it is undervalued in the current market context.